Isomorphic Labs, a Google DeepMind spinoff, will soon start human trials of drugs designed using its Nobel Prize–winning AI protein-folding technology.

At a Google DeepMind town hall, VP Tom Lue and CEO Demis Hassabis told employees the company is actively expanding national security AI contracts with the Pentagon, having removed its previous pledge against weapons-related AI use.

Isomorphic Labs, the DeepMind spin-off focused on AI-driven drug discovery, has revealed an exclusive new AI model that scientists say surpasses current benchmarks, offering a glimpse of what AlphaFold 4 may bring to pharmaceutical research and molecular biology.

Former Google DeepMind researcher David Silver is raising a record $1 billion seed round led by Sequoia Capital for his London-based startup Ineffable Intelligence, which aims to build superintelligence using reinforcement learning rather than large language models.

Demis Hassabis identifies dual-use AI risks and calls for international frameworks, predicting AGI arrival within 5-10 years at India summit.

Demis Hassabis reveals 17 AI drug development projects at Davos, predicting robotics breakthrough and golden age of scientific discovery.

Google enhances Gemini 3 Deep Think for complex scientific tasks and launches Aletheia, an AI agent that solved 91.9% of advanced mathematics problems.

Google unveils comprehensive AI strategy for Singapore including new R&D capabilities, AI Living Labs, and workforce development programs to build AI-ready nation.

Waymo reveals generative simulation model built on Google DeepMind's Genie 3 to train self-driving systems on edge scenarios like extreme weather.

Google DeepMind's AI platform analyzes athlete motion from smartphone video, helping Team USA prepare for 2026 Winter Olympics.

Google DeepMind unveils AlphaGenome, an open-source AI model capable of analyzing DNA sequences up to one million base pairs in length and predicting how genetic variations affect gene regulation. The breakthrough technology can decode 98% of the human genome, including previously mysterious non-coding DNA regions, potentially revolutionizing cancer research, rare disease diagnosis, and personalized medicine by identifying disease-causing genetic mutations with unprecedented accuracy.

Google DeepMind unveils AlphaGenome, a groundbreaking AI tool that analyzes up to 1 million letters of DNA code to predict how mutations affect gene regulation, potentially paving the way for new treatments for heart disease, cancer, and autoimmune disorders.

DeepMind CEO Demis Hassabis says AI industry not in bubble but warns of excess funding in startups with no products, citing unsustainable multi-billion seed rounds.

Google DeepMind CEO Demis Hassabis suggests that the natural shortcomings slowing down AI's development might be a good thing, allowing more time to address the societal and philosophical challenges of the technology.

Google DeepMind CEO Demis Hassabis predicts the next trillion-dollar AI wave will be in 'Physical AI'—systems that interact with the real world, with companies like 51WORLD leading the charge.

Google DeepMind CEO Demis Hassabis argues that large language models like ChatGPT are insufficient for true scientific breakthroughs and that 'world models' are the future of AI.

Demis Hassabis reveals daily strategic conversations with Google CEO Sundar Pichai as DeepMind intensifies competition with OpenAI.